Treating nasal polyps with monoclonal antibodies marks a new chapter in ENT medicine
Researchers at Sechenov University have begun using monoclonal antibodies to treat nasal polyps, and clinicians report noticeable improvements after the very first injection. This approach represents a breakthrough in world medicine and is being explored in the field of otolaryngology for the first time. The university’s press team shared these developments with the media.
According to the ICM Ear, Nose and Throat Diseases Department at NV Sklifosovsky, chief otolaryngologist of the Central Federal District Valery Svistushkin explained that patients felt dramatic relief after the initial treatment. Some patients reported an immediate sense of relief, and over three to four months the doctors observed sustained improvement with both nasal passages and sinuses showing a marked reduction in polyp tissue.
The procedure not only restores normal nasal breathing, smell, and sleep quality, but it also lowers the risk of recurrent ear and respiratory infections. Traditionally, polyps are managed with surgery or corticosteroid therapy. The monoclonal antibody regimen consists of injections into the shoulder twice a month, providing a non-surgical path for many patients.
In a cohort of roughly one hundred individuals, the monoclonal antibodies targeted a specific inflammatory pathway that drives polyp growth and recurrence. This targeted approach helped patients avoid surgery and the associated anesthesia, stress, and lengthy recovery. In rare cases some polyps may reappear, and surgery could be considered again, but the expected scope of intervention would be smaller and anesthesia less likely to be required.
Another advantage is that patients on this antibody therapy typically do not need hormonal corticosteroids. Corticosteroids may offer short term benefit but carry potential systemic side effects and do not provide a long term solution for many patients. The monoclonal antibody protocol aims to reduce polyp activity while minimizing wider health risks.
In related news, researchers have pointed to advances in cancer detection where accuracy reaches about 83 percent without invasive colonoscopy, underscoring a broader push toward safer, less invasive diagnostic and treatment options across medicine.
These developments offer potential implications for patients across North America, including Canada and the United States, as clinicians evaluate how monoclonal antibody therapy for nasal polyps could fit into existing treatment pathways and insurance coverage. They highlight a trend toward personalized medicine, where therapy is tailored to the underlying inflammatory processes rather than relying solely on surgery or broad-spectrum medications. Marked results in early trials are encouraging, and ongoing studies are expected to clarify long term outcomes and any patient selection criteria that optimize benefit.
Ultimately, the goal for patients living with nasal polyps is clearer breathing, improved sense of smell, better sleep, and a reduced risk of secondary infections. The monoclonal antibody approach offers a promising alternative that can spare many people from major surgery, while enhancing overall quality of life. Further research and real world experience will determine how widely this therapy becomes part of standard otolaryngology practice and how it will be positioned within Canada and the United States healthcare systems as new guidelines emerge.
Notes for readers indicate that early responses are promising and that science continues to refine treatment protocols to balance efficacy with safety across diverse patient populations. Clinicians emphasize the importance of monitoring and personalized care to ensure the best possible outcomes for individuals with nasal polyps.
Related posts:
The goalscorers of Lionel Scaloni’s cycle in the Argentina national team Gastrointestinal Polyps: Types, Risks, and Management in Modern Care Nasal Irrigation Safety and Best Practices for Children and Adults Biocad Tops Russia’s Antitumor Drug Market IQVIA Confirms Differences in Inflammatory Arthritis: Causes, Treatments, and Personalization Monoclonal Vaccine Trial Advances at Gamaleya Center Breathing Through the Nose: How Nasal Breathing Impacts Performance and Health Breakthrough monoclonal antibody shows promise against rabies in animals Evusheld in Europe: Approval, dosing, and impact on high-risk groups against COVID-19 Broad-Spectrum Antibody Targets SARS-CoV-2 Variants, Including Omicron, with Potential Clinical Impact Regular Screening for Digestive Polyps: Importance, Detection, and Safe Management Septoplasty vs nasal sprays for deviated septum: study insights